Long-term beneficial effect of tacrolimus conversion on renal transplant recipients

Renal Failure

Volumn 27, Issue 5, 2005, Pages 501-506

  Lee, Wen Chin ^a,b   Lian, Jong Da ^b   Wu, Ming Ju ^a   Cheng, Chi Hung ^a   Chen, Cheng Hsu ^a   Shu, Kuo Hsiung ^a,b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acute rejection; Chronic allograft nephropathy; Conversion; Cyclosporine; Tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; CYCLOSPORIN; TACROLIMUS; TRIACYLGLYCEROL;

ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; FEMALE; GINGIVA HYPERTROPHY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HIRSUTISM; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CHI-SQUARE DISTRIBUTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 24044448604     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220500198086     Document Type: Article

References (27)

1. Cecka, J.; Cho, Y.; Terasaki, P. Analysis of the UNOS scientific renal transplant registry at three years - early events affecting transplant success. Transplantation 1992, 53, 59-64.
2. Frey, D.; Matas, A.; Gillingham, K.J.; Canafax, D.; Payne, W.D.; Dunn, D.L.; et al. Sequential therapy - a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992, 54, 50-56.
3. Graham, R. Cyclosporine: mechanisms of action and toxicity. Clevel. Clin. J. Med. 1994, 61, 308-313.
4. Kohnle, M.; Zimmermann, U.; Lutkes, P.; Albrecht, K.H.; Philipp, T.; Heemann, U. Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. Transplant. Int. 2000, 13 (Suppl.), S345-S348.
5. Tanabe, K.; Ishikawa, N.; Tokumoto, K.; Takahashi, K.; Oshima, T.; Fuchinoue, S.; et al. Factors affecting long-term renal allograft survival in cyclosporine-treated kidney transplants. Transplant. Proc. 1998, 30, 1805-1809.
6. Goto, T.; Kino, T.; Hatanaka, H.; Okuhara, M.; Kohsaka, M.; Aoki, H.; et al. FK506: historical perspectives. Transplant. Proc. 1991, 23, 2713-2717.
7. Kaplan, B.; Schold, J.D.; Meier-Kriesche, H.U. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J. Am. Soc. Nephrol. 2003, 14, 2980-2984.
8. Kelly, D.; Jara, P.; Rodeck, B.; Lykavieris, P.; Burdelski, M.; Becker, M.; et al. Tacrolimus and steroids versus cyclosporine microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomized European multicenter trial. Lancet 2004, 364, 1054-1061.
9. Urbizu, J.M.; Zarraga, S.; Gomez-Ullate, P.; Amenabar, J.J.; Gainza, F.I.; Lampreabe, I.; et al. Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant patients treated with cyclosporine. Transplant. Proc. 2003, 35, 1704-1705.
10. Peters, D.H.; Fitton, A.; Plosker, G.L.; Faulds, D. Tacrolimus: a review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993, 46, 746-794.
11. Shu, K.H.; Cheng, C.H.; Wu, M.J.; Lian, J.D.; Huang, C.C.; Chu, S.H.; et al. A multicenter trial of FK506 as rescue therapy for renal transplant recipients in Taiwan. Transplant. Proc. 1998, 30, 3584-3586.
12. Lo, J.C.; Chertow, G.M.; Go, A.S.; Hsu, C.Y. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005, 67, 1047-1052.
13. Levey, A.S.; Greene, T.; Kusek, J.W.; Beck, G.J. A simplified equation to predict glomerular filtration rate from serum creatinine. J. Am. Soc. Nephrol. 2000, 11, 155A.
14. Levey, A.S.; Bosch, J.P.; Lewis, J.B.; et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 1999, 130, 461-470.
15. Woodle, E.S.; Perdrizet, G.A.; So, S.; Jendrisak, M.D.; White, H.M.; Marsh, J.W. FK 506 rescue therapy: early conversion improves efficacy. Transplant. Proc. 1993, 25, 1990-1991.
16. Jordan, M.L.; Naraghi, R.; Shapiro, R.; Smith, D.; Vivas, C.A.; Scantlebury, V.P.; et al. Tacrolimus for rescue of refractory renal allograft rejection. Transplant. Proc. 1998, 30, 1257-1260.
17. Manu, M.A.; Tanabe, K.; Ishikawa, N.; Tokumoto, T.; Oshima, T.; Shinmura, H.; et al. Tacrolimus rescue for resistant rejection, chronic rejection and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. Transplant. Proc. 1999, 31, 2853-2855.
18. Budde, K.; Smettan, S.; Fritsche, L.; Waiser, J.; Neumayer, H.H. Five-year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. Transplant. Proc. 2002, 34, 1594-1596.
19. Morrissey, P.E.; Gohh, R.; Shaffer, D.; Crosson, A.; Madras, P.N.; Sahyoun, A.I.; et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation 1997, 63, 845-848.
20. Olyaei, A.J.; de Mattos, A.M.; Bennett, W.M. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr. Opin. Crit. Care 2001, 7, 384-389.
21. Vieira, J.M.J.; Noronha, I.L.; Malheiros, D.M.; Burdmann, E.A. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation 1999, 68, 1746-1753.
22. Baan, C.C.; van Riemsdijk-van Overbeeke, I.C.; Balk, A.H.; Vantrimpont, P.M.; Mol, W.M.; Knoop, C.J.; et al. Conversion from cyclosporine A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expression. Clin. Transplant. 2001, 15, 276-283.
23. Ebbs, A.; Pan, F.; Wynn, C.; Erickson, L.; Kobayashi, M.; Jiang, H. Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration. Transplant. Proc. 2002, 34, 1378-1381.
24. Jiang, H.; Yang, X.F.; Wynn, C.; Soriano, R.; Krishnan, K.; Fujimura, T.; et al. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. Transplant. Proc. 2001, 33, 510-513.
25. Jiang, H.; Yang, X.; Soriano, R.; Fujitus, T.; Kobayashi, M. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. Transplant. Proc. 1999, 31, 1203-1205.
26. Jiang, H.; Wynn, C.; Pan, F.; Ebbs, A.; Erikson, L.M.; Kobayashi, M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. Transplantation 2002, 73, 1808-1817.
27. Jordan, M.L.; Shapiro, R.; Vivas, C.A.; Scantlebury, V.P.; Rhandhawa, P.; Carrieri, G.; et al. FK 506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994, 57, 860-865.